CC
MED icon

Clearline Capital’s Medifast MED Stock Holding History

Clearline Capital’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,351
Closed -$459K – 83
2020
Q1 		$459K Sell
7,351
-1,355
-16% -$123K 0.21% 56
2019
Q4 		$954K Sell
8,706
-67,499
-89% -$6.53M 0.41% 47
2019
Q3 		$7.9M Buy
+76,205
New +$8.19M 3.6% 7

Other funds holding MED

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Clearline Capital's MED Position: Q2 2020 in Review

Clearline Capital sold out of Medifast (MED) in Q2 2020, closing a stake of 7,351 shares — an estimated $459K sold.

Clearline Capital first reported a position in MED in Q3 2019 and held it in 3 quarters. The position peaked at $7.9M in Q3 2019. 224 funds tracked by Wall St. Rank hold MED as of Q2 2020.

  • Clearline Capital reported no remaining Medifast position as of Q2 2020 after selling out during the quarter.
  • Clearline Capital sold 7,351 Medifast shares in Q2 2020, an estimated $459K.
  • Clearline Capital first reported a position in Medifast in Q3 2019 and held it in 3 quarters.
  • Clearline Capital's Medifast position peaked at $7.9M in Q3 2019.
  • 224 funds tracked by Wall St. Rank held Medifast as of Q2 2020.

Based on Clearline Capital's 13F filing for Q2 2020, filed 14 Aug 2020.